Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kamanna, V. S.
Right arrow Articles by Kirschenbaum, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamanna, V. S.
Right arrow Articles by Kirschenbaum, M. A.

Journal of the American Society of Nephrology, Vol 5, 193-200, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line

VS Kamanna, ML Kashyap, R Pai, DT Bui, FY Jin, DD Roh, GM Shah and MA Kirschenbaum
Section of Nephrology, Department of Veterans Affairs Medical Center, Long Beach, CA 90822.

Abnormalities in lipoprotein metabolism are common in uremic patients and may represent an additional risk factor for the development of atherosclerosis. Despite the frequent occurrence of lipoprotein abnormalities, the role of various serum toxins and subfractions that accumulate in uremic patients on lipoprotein metabolism is not clearly understood. This study addressed the role of uremic toxins on lipoprotein metabolism by examining the effect of a 500 to 2,000-d subfraction obtained from the serum of uremic and control subjects on the synthesis of apolipoprotein (apo) A-I in a human hepatoma cell line (Hep-G2). Serum subfractions obtained from uremic patients inhibited apo A-I synthesis and secretion by Hep-G2 cells in a dose-dependent manner as measured by (3H)leucine incorporation into apo A-I, immunoprecipitation, and ELISA. The uremic serum subfraction decreased the mRNA expression for apo A-I in Hep-G2 cells when compared with controls. These observations suggest that a component of uremic serum can have the potential to inhibit hepatic apo A-I synthesis and may adversely influence high-density lipoprotein metabolism, thus increasing the risk for the development of atherosclerotic vascular complications in uremic patients.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
C. H. Beerenhout, J. P. Kooman, A. J. Luik, S. G. J. Jeuken-Mertens, F. M. van der Sande, and K. M. L. Leunissen
Optimizing renal replacement therapy--a case for online filtration therapies?
Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2065 - 2070.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. VANHOLDER and R. DE SMET
Pathophysiologic Effects of Uremic Retention Solutes
J. Am. Soc. Nephrol., August 1, 1999; 10(8): 1815 - 1823.
[Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673